Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Assessment of NICE and USPSTF guidelines for identifying women at high risk of pre-eclampsia for tailoring aspirin prophylaxis in pregnancy: An individual participant data meta-analysis.

Al-Rubaie ZTA, Askie LM, Hudson HM, Ray JG, Jenkins G, Lord SJ.

Eur J Obstet Gynecol Reprod Biol. 2018 Sep 2;229:159-166. doi: 10.1016/j.ejogrb.2018.08.587. [Epub ahead of print]

PMID:
30199814
2.

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis.

Sjoquist KM, Lord SJ, Friedlander ML, John Simes R, Marschner IC, Lee CK.

Ther Adv Med Oncol. 2018 Aug 6;10:1758835918788500. doi: 10.1177/1758835918788500. eCollection 2018.

3.

Practical guide for identifying unmet clinical needs for biomarkers.

Monaghan PJ, Robinson S, Rajdl D, Bossuyt PMM, Sandberg S, St John A, O'Kane M, Lennartz L, Röddiger R, Lord SJ, Cobbaert CM, Horvath AR.

EJIFCC. 2018 Jul 11;29(2):129-137. eCollection 2018 Jul.

4.

Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016).

Daniels B, Girosi F, Tervonen H, Kiely BE, Lord SJ, Houssami N, Pearson SA.

PLoS One. 2018 Jul 26;13(7):e0198152. doi: 10.1371/journal.pone.0198152. eCollection 2018.

5.

Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer.

Elmadahm A, Lord SJ, Hudson HM, Lee CK, Buizen L, Farshid G, Gebski VJ, Gill PG.

Breast. 2018 Oct;41:82-88. doi: 10.1016/j.breast.2018.05.011. Epub 2018 Jun 26.

PMID:
30007272
6.

Concise Language Promotes Clear Thinking about Cell Shape and Locomotion.

Fritz-Laylin LK, Lord SJ, Kakley M, Mullins RD.

Bioessays. 2018 Jul;40(7):e1700225. doi: 10.1002/bies.201700225. Epub 2018 May 30. No abstract available.

PMID:
29846958
7.

Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).

Daniels B, Kiely BE, Lord SJ, Houssami N, Lu CY, Ward RL, Pearson SA.

Breast Cancer Res Treat. 2018 May 7. doi: 10.1007/s10549-018-4804-0. [Epub ahead of print]

PMID:
29736743
8.

Total Hip Arthroplasty by the Direct Anterior Approach Using a Neck-preserving Stem: Safety, efficacy and learning curve.

Khemka A, Mograby O, Lord SJ, Doyle Z, Al Muderis M.

Indian J Orthop. 2018 Mar-Apr;52(2):124-132. doi: 10.4103/ortho.IJOrtho_314_16.

9.

Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016).

Daniels B, Kiely BE, Lord SJ, Houssami N, Lu CY, Ward RL, Pearson SA.

Breast. 2018 Apr;38:7-13. doi: 10.1016/j.breast.2017.11.007. Epub 2017 Nov 21.

PMID:
29172171
10.

ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome): A Study of Cross-System Implementation of a National Clinical Pathway.

Than MP, Pickering JW, Dryden JM, Lord SJ, Aitken SA, Aldous SJ, Allan KE, Ardagh MW, Bonning JWN, Callender R, Chapman LRE, Christiansen JP, Cromhout APJ, Cullen L, Deely JM, Devlin GP, Ferrier KA, Florkowski CM, Frampton CMA, George PM, Hamilton GJ, Jaffe AS, Kerr AJ, Larkin GL, Makower RM, Matthews TJE, Parsonage WA, Peacock WF, Peckler BF, van Pelt NC, Poynton L, Richards AM, Scott AG, Simmonds MB, Smyth D, Thomas OP, To ACY, Du Toit SA, Troughton RW, Yates KM; ICare-ACS Implementation Group.

Circulation. 2018 Jan 23;137(4):354-363. doi: 10.1161/CIRCULATIONAHA.117.031984. Epub 2017 Nov 14.

PMID:
29138293
11.

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).

Daniels B, Kiely BE, Houssami N, Lord SJ, Dobbins T, Lu CY, Ward RL, Pearson SA.

Br J Cancer. 2018 Feb 6;118(3):441-447. doi: 10.1038/bjc.2017.405. Epub 2017 Nov 14.

PMID:
29136405
12.

Actin-based protrusions of migrating neutrophils are intrinsically lamellar and facilitate direction changes.

Fritz-Laylin LK, Riel-Mehan M, Chen BC, Lord SJ, Goddard TD, Ferrin TE, Nicholson-Dykstra SM, Higgs H, Johnson GT, Betzig E, Mullins RD.

Elife. 2017 Sep 26;6. pii: e26990. doi: 10.7554/eLife.26990.

13.

Our evolving view of cell motility.

Fritz-Laylin LK, Lord SJ, Mullins RD.

Cell Cycle. 2017 Oct 2;16(19):1735-1736. doi: 10.1080/15384101.2017.1360655. Epub 2017 Aug 18. No abstract available.

14.

How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.

Velentzis LS, Caruana M, Simms KT, Lew JB, Shi JF, Saville M, Smith MA, Lord SJ, Tan J, Bateson D, Quinn M, Canfell K.

Int J Cancer. 2017 Dec 15;141(12):2410-2422. doi: 10.1002/ijc.30926. Epub 2017 Oct 5.

PMID:
28801947
15.

WASP and SCAR are evolutionarily conserved in actin-filled pseudopod-based motility.

Fritz-Laylin LK, Lord SJ, Mullins RD.

J Cell Biol. 2017 Jun 5;216(6):1673-1688. doi: 10.1083/jcb.201701074. Epub 2017 May 4.

16.

Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collaborative Meta-analysis.

Pickering JW, Than MP, Cullen L, Aldous S, Ter Avest E, Body R, Carlton EW, Collinson P, Dupuy AM, Ekelund U, Eggers KM, Florkowski CM, Freund Y, George P, Goodacre S, Greenslade JH, Jaffe AS, Lord SJ, Mokhtari A, Mueller C, Munro A, Mustapha S, Parsonage W, Peacock WF, Pemberton C, Richards AM, Sanchis J, Staub LP, Troughton R, Twerenbold R, Wildi K, Young J.

Ann Intern Med. 2017 May 16;166(10):715-724. doi: 10.7326/M16-2562. Epub 2017 Apr 18. Erratum in: Ann Intern Med. 2017 Oct 3;167(7):528.

17.

Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma.

Levert-Mignon A, Bourke MJ, Lord SJ, Taylor AC, Wettstein AR, Edwards M, Botelho NK, Sonson R, Jayasekera C, Fisher OM, Thomas ML, Macrae F, Hussey DJ, Watson DI, Lord RV.

United European Gastroenterol J. 2017 Feb;5(1):13-20. doi: 10.1177/2050640616650794. Epub 2016 Jul 7.

18.

Reversibility of nerve root sedimentation sign in lumbar spinal stenosis patients after decompression surgery.

Barz C, Melloh M, Staub LP, Lord SJ, Merk HR, Barz T.

Eur Spine J. 2017 Oct;26(10):2573-2580. doi: 10.1007/s00586-017-4962-5. Epub 2017 Feb 4.

PMID:
28161752
19.

Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.

Daniels B, Lord SJ, Kiely BE, Houssami N, Haywood P, Lu CY, Ward RL, Pearson SA; HER2 therapy observational study (HER2-OBS) investigators.

BMJ Open. 2017 Jan 24;7(1):e014439. doi: 10.1136/bmjopen-2016-014439.

20.

Driving After Microinvasive Total Hip Arthroplasty.

Qurashi S, Chinnappa J, Lord SJ, Nazha A, Gordon J, Chow J.

J Arthroplasty. 2017 May;32(5):1525-1529. doi: 10.1016/j.arth.2016.11.052. Epub 2016 Dec 20.

PMID:
28057395
21.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK.

J Thorac Oncol. 2017 Apr;12(4):633-643. doi: 10.1016/j.jtho.2016.11.2236. Epub 2016 Dec 19.

22.
23.

CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy.

Fisher OM, Levert-Mignon AJ, Lehane CW, Botelho NK, Maag JL, Thomas ML, Edwards M, Lord SJ, Bobryshev YV, Whiteman DC, Lord RV.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):746-754. Epub 2016 Aug 30.

PMID:
27577713
24.

The Deckled Incision: Study Protocol for a Randomized Controlled Trial.

Singla A, Lord SJ, Ngo Q.

JMIR Res Protoc. 2016 Jul 12;5(3):e97. doi: 10.2196/resprot.5491.

25.

Biomarker development targeting unmet clinical needs.

Monaghan PJ, Lord SJ, St John A, Sandberg S, Cobbaert CM, Lennartz L, Verhagen-Kamerbeek WD, Ebert C, Bossuyt PM, Horvath AR; Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine.

Clin Chim Acta. 2016 Sep 1;460:211-9. doi: 10.1016/j.cca.2016.06.037. Epub 2016 Jun 30.

PMID:
27374304
26.

The Osseointegration Group of Australia Accelerated Protocol (OGAAP-1) for two-stage osseointegrated reconstruction of amputated limbs.

Muderis MA, Tetsworth K, Khemka A, Wilmot S, Bosley B, Lord SJ, Glatt V.

Bone Joint J. 2016 Jul;98-B(7):952-60. doi: 10.1302/0301-620X.98B7.37547.

PMID:
27365474
27.

Safety of Osseointegrated Implants for Transfemoral Amputees: A Two-Center Prospective Cohort Study.

Al Muderis M, Khemka A, Lord SJ, Van de Meent H, Frölke JP.

J Bone Joint Surg Am. 2016 Jun 1;98(11):900-9. doi: 10.2106/JBJS.15.00808.

PMID:
27252434
29.

Effectiveness of EDACS Versus ADAPT Accelerated Diagnostic Pathways for Chest Pain: A Pragmatic Randomized Controlled Trial Embedded Within Practice.

Than MP, Pickering JW, Aldous SJ, Cullen L, Frampton CM, Peacock WF, Jaffe AS, Goodacre SW, Richards AM, Ardagh MW, Deely JM, Florkowski CM, George P, Hamilton GJ, Jardine DL, Troughton RW, van Wyk P, Young JM, Bannister L, Lord SJ.

Ann Emerg Med. 2016 Jul;68(1):93-102.e1. doi: 10.1016/j.annemergmed.2016.01.001.

30.

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.

Lee CK, Davies L, Gebski VJ, Lord SJ, Di Leo A, Johnston S, Geyer C Jr, Cameron D, Press MF, Ellis C, Loi S, Marschner I, Simes J, de Souza P.

J Clin Oncol. 2016 Mar 20;34(9):936-44. doi: 10.1200/JCO.2015.62.4767. Epub 2016 Jan 25.

PMID:
26811533
31.

Osseointegrated total hip replacement connected to a lower limb prosthesis: a proof-of-concept study with three cases.

Khemka A, FarajAllah CI, Lord SJ, Bosley B, Al Muderis M.

J Orthop Surg Res. 2016 Jan 19;11:13. doi: 10.1186/s13018-016-0348-3.

32.

The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.

Fisher OM, Lord SJ, Falkenback D, Clemons NJ, Eslick GD, Lord RV.

Gut. 2017 Mar;66(3):399-410. doi: 10.1136/gutjnl-2015-310888. Epub 2016 Jan 5. Review.

33.

Minimally invasive medial patellofemoral ligament reconstruction for patellar instability using an artificial ligament: A two year follow-up.

Khemka A, Lord SJ, Doyle Z, Bosley B, Al Muderis M.

Knee. 2016 Mar;23(2):261-6. doi: 10.1016/j.knee.2015.07.002. Epub 2015 Aug 12.

PMID:
26275579
34.

Australian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority Areas.

Lam J, Lord SJ, Hunter KE, Simes RJ, Vu T, Askie LM.

Med J Aust. 2015 Jul 20;203(2):97-101.

PMID:
26175250
35.

Osseointegrated total knee replacement connected to a lower limb prosthesis: 4 cases.

Khemka A, Frossard L, Lord SJ, Bosley B, Al Muderis M.

Acta Orthop. 2015;86(6):740-4. doi: 10.3109/17453674.2015.1068635. Epub 2015 Aug 27.

36.

Setting analytical performance specifications based on outcome studies - is it possible?

Horvath AR, Bossuyt PM, Sandberg S, John AS, Monaghan PJ, Verhagen-Kamerbeek WD, Lennartz L, Cobbaert CM, Ebert C, Lord SJ; Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine.

Clin Chem Lab Med. 2015 May;53(6):841-8. doi: 10.1515/cclm-2015-0214. Review.

37.

The relative benefits and costs of solid phase bead technology to detect preformed donor specific antihuman leukocyte antigen antibodies in determining suitability for kidney transplantation.

Nguyen HT, Lim WH, Craig JC, Chapman JR, Lord SJ, Howard K, Wong G.

Transplantation. 2015 May;99(5):957-64. doi: 10.1097/TP.0000000000000697.

PMID:
25943234
38.

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC.

J Clin Oncol. 2015 Jun 10;33(17):1958-65. doi: 10.1200/JCO.2014.58.1736. Epub 2015 Apr 20.

PMID:
25897154
39.

MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma.

Fisher OM, Levert-Mignon AJ, Lord SJ, Lee-Ng KK, Botelho NK, Falkenback D, Thomas ML, Bobryshev YV, Whiteman DC, Brown DA, Breit SN, Lord RV.

Br J Cancer. 2015 Apr 14;112(8):1384-91. doi: 10.1038/bjc.2015.100. Epub 2015 Mar 17.

40.

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, Casali PG, Maki RG, Cioffi A, Mcarthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P.

Eur J Cancer. 2015 May;51(7):852-60. doi: 10.1016/j.ejca.2015.02.015. Epub 2015 Mar 19.

PMID:
25801699
41.

Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma.

Whiteman DC, Appleyard M, Bahin FF, Bobryshev YV, Bourke MJ, Brown I, Chung A, Clouston A, Dickins E, Emery J, Eslick GD, Gordon LG, Grimpen F, Hebbard G, Holliday L, Hourigan LF, Kendall BJ, Lee EY, Levert-Mignon A, Lord RV, Lord SJ, Maule D, Moss A, Norton I, Olver I, Pavey D, Raftopoulos S, Rajendra S, Schoeman M, Singh R, Sitas F, Smithers BM, Taylor AC, Thomas ML, Thomson I, To H, von Dincklage J, Vuletich C, Watson DI, Yusoff IF.

J Gastroenterol Hepatol. 2015 May;30(5):804-20. doi: 10.1111/jgh.12913. Review.

PMID:
25612140
42.

High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.

Fisher OM, Levert-Mignon AJ, Lord SJ, Botelho NK, Freeman AK, Thomas ML, Falkenback D, Wettstein A, Whiteman DC, Bobryshev YV, Lord RV.

Ann Surg Oncol. 2015 Jul;22(7):2431-8. doi: 10.1245/s10434-014-4155-y. Epub 2014 Oct 28.

43.

A conceptual model of compensation/decompensation in lumbar segmental instability.

Barz T, Melloh M, Lord SJ, Kasch R, Merk HR, Staub LP.

Med Hypotheses. 2014 Sep;83(3):312-6. doi: 10.1016/j.mehy.2014.06.003. Epub 2014 Jun 12.

PMID:
25001025
44.

Spatial organization of EphA2 at the cell-cell interface modulates trans-endocytosis of ephrinA1.

Greene AC, Lord SJ, Tian A, Rhodes C, Kai H, Groves JT.

Biophys J. 2014 May 20;106(10):2196-205. doi: 10.1016/j.bpj.2014.03.043.

45.

Esophageal dysmotility after laparoscopic gastric band surgery.

Le Page PA, Kwon S, Lord SJ, Lord RV.

Obes Surg. 2014 Apr;24(4):625-30. doi: 10.1007/s11695-013-1134-5.

PMID:
24258146
46.

Increased intraoperative epidural pressure in lumbar spinal stenosis patients with a positive nerve root sedimentation sign.

Barz T, Melloh M, Staub LP, Lord SJ, Lange J, Merk HR.

Eur Spine J. 2014 May;23(5):985-90. doi: 10.1007/s00586-013-3071-3. Epub 2013 Oct 29.

PMID:
24166020
47.

A 2-hour diagnostic protocol for possible cardiac chest pain in the emergency department: a randomized clinical trial.

Than M, Aldous S, Lord SJ, Goodacre S, Frampton CM, Troughton R, George P, Florkowski CM, Ardagh M, Smyth D, Jardine DL, Peacock WF, Young J, Hamilton G, Deely JM, Cullen L, Richards AM.

JAMA Intern Med. 2014 Jan;174(1):51-8. doi: 10.1001/jamainternmed.2013.11362.

PMID:
24100783
48.

From biomarkers to medical tests: the changing landscape of test evaluation.

Horvath AR, Lord SJ, StJohn A, Sandberg S, Cobbaert CM, Lorenz S, Monaghan PJ, Verhagen-Kamerbeek WD, Ebert C, Bossuyt PM; Test Evaluation Working Group of the European Federation of Clinical Chemistry Laboratory Medicine.

Clin Chim Acta. 2014 Jan 1;427:49-57. doi: 10.1016/j.cca.2013.09.018. Epub 2013 Sep 27.

PMID:
24076255
49.

Clinical validity of the nerve root sedimentation sign in patients with suspected lumbar spinal stenosis.

Barz T, Staub LP, Melloh M, Hamann G, Lord SJ, Chatfield MD, Bossuyt PM, Lange J, Merk HR.

Spine J. 2014 Apr;14(4):667-74. doi: 10.1016/j.spinee.2013.06.105. Epub 2013 Sep 20.

PMID:
24055611
50.

Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.

Martin AJ, Lord SJ, Verry HE, Stockler MR, Emery JD.

Med J Aust. 2013 Jun 3;198(10):546-50. Erratum in: Med J Aust. 2014 Mar 3;200(4):205.

PMID:
23725269

Supplemental Content

Support Center